-
2023-509146-35-00
6
2025-01-30
Systemic Lupus Erythematosus
-
2024-519825-39-00
4
2025-01-30
Locally advanced colon cancer (LACC)
-
2024-511596-15-00
4
2024-12-26
Liver Diseases, Alcoholic
-
2024-519759-27-00
6
2024-12-20
Acute Hypoxemic Respiratory Failure
-
2023-508813-18-00
4
2024-12-18
Refractory Focal Onset Epilepsy
-
2023-509717-36-00
5
2024-12-16
AF patients who have undergone successful PCI
-
2023-504022-19-01
5
2024-12-13
Polymyositis or dermatomyositis according to 2017 EULAR / ACR classifi
-
2024-512279-10-00
5
2024-11-25
Triple Negative Breast Cancer
-
2024-511465-11-00
5
2024-11-20
Spontaneous lobar ICH
-
2024-514354-67-00
5
2024-11-01
Systemic lupus erythematosus
-
2024-512194-27-01
6
2024-10-21
Patients receiving oral anticoagulant therapy who are scheduled for el
-
2024-514304-14-00
1
2024-10-08
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
-
2023-508811-21-00
10
2024-09-25
Refractory Focal Onset Epilepsy
-
2022-502408-57-00
5
2024-09-04
Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav
-
2023-510213-25-01
6
2024-07-08
Takotsubo Syndrome (TT) is an acute cardiac condition
-
2024-511959-18-01
5
2024-07-01
Acute Pulmonary Embolism
-
2023-505860-12-00
5
2024-06-26
Chronic postsurgical pain after inguinal hernia repair
-
2023-505929-14-00
5
2024-05-21
Systemic Lupus Erythematosus
-
2023-505024-62-01
4
2024-05-16
Oligometastatic patients with castration-resistant
prostate cancer
-
2023-504151-27-00
5
2024-05-09
Psychosis associated with Alzheimer’s Disease
-
2023-505791-30-01
10
2024-04-17
Diabetic Retinopathy
-
2023-505251-43-00
5
2024-02-28
Primary Biliary Cholangitis
-
2023-504863-17-00
5
2024-02-21
1. Lupus Erythematosus, Cutaneous, Subacute
2. Chronic Cutaneous Lupus
-
2022-502282-24-00
5
2024-02-14
Primary generalized tonic-clonic seizures